Saturday, 17 October 2026European Markets

HØLAND OG SETSKOG Stock Slides 9% At Session Start On Tuesday, Underperforms Market

Loading stream...

(VIANEWS) - Shares of HØLAND OG SETSKOG (Oslo Børs All-share Index_GI: HSPG.OL) slid 9.62% to kr141.00 at 10:39 EST on Tuesday, after five successive sessions in a row of losses. Oslo Børs All-share Index_GI is jumping 0.12% to kr1,417.68, after five successive sessions in a row of losses. This seems, up until now, a somewhat positive trend exchanging session today.

About HØLAND OG SETSKOG

Høland og Setskog Sparebank provides banking services for the retail and corporate markets in Norway. It offers deposits and loans, as well as insurance products. The company was formerly known as Holand Sparebank and changed its name to Høland og Setskog Sparebank in 2010. The company was founded in 1849 and is headquartered in Bjørkelangen, Norway.

Earnings Per Share

As for profitability, HØLAND OG SETSKOG has a trailing twelve months EPS of kr77.15.

PE Ratio

HØLAND OG SETSKOG has a trailing twelve months price to earnings ratio of 1.83. Meaning, the purchaser of the share is investing kr1.83 for every norwegian krone of annual earnings.

More news about HØLAND OG SETSKOG (HSPG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com